Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.51
- Piotroski Score 6.00
- Grade Overweight
- Symbol (AMPH)
- Company Amphastar Pharmaceuticals, Inc.
- Price $48.49
- Changes Percentage (0.98%)
- Change $0.47
- Day Low $48.00
- Day High $49.22
- Year High $65.92
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Last Earnings 06/07/2010
- Ex-Dividend for 5/16 Dividend 06/11/2010
- Dividend Payable 06/30/2010
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $66.00
- High Stock Price Target $66.00
- Low Stock Price Target $66.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.91
- Trailing P/E Ratio 13.99
- Forward P/E Ratio 13.99
- P/E Growth 13.99
- Net Income $137.55 M
Income Statement
Quarterly
Annual
Latest News of AMPH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amphenol Cl A Clears Key Benchmark, Hitting 80-Plus RS Rating
Learn how to scale out of losing stocks using three signals, including the Relative Strength (RS) Rating which rates a stock's technical performance from 1 to 99. Stocks with RS Ratings above 80 often...
By Investor's Business Daily | 1 week ago -
Amphenol Corporation (NYSE:APH): A Chip Stock Powering The AI Boom
AI has driven semiconductor growth, with NVIDIA reporting record revenues from AI chip sales. Demand for advanced chips for AI tasks is rising, with Gartner predicting 70% of new AI apps by 2025 will ...
By Yahoo! Finance | 1 week ago -
Amphenol Corporation (APH): Short Seller Sentiment Is Bullish
The article discusses the performance of Amphenol Corporation (NYSE:APH) among American tech stocks. It highlights the company's strengths in the electrical component market and its positive outlook, ...
By Yahoo! Finance | 3 weeks ago
